MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.290
-0.030
-1.29%
Closed 16:00 07/14 EDT
OPEN
2.320
PREV CLOSE
2.320
HIGH
2.380
LOW
2.274
VOLUME
144.71K
TURNOVER
--
52 WEEK HIGH
23.10
52 WEEK LOW
1.600
MARKET CAP
10.49M
P/E (TTM)
-0.1409
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PHIO stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.

EPS

PHIO News

More
Phio Pharmaceuticals Files Patent Application For 'Chemically Modified Oligonucleotides'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20200215113&OS=20200215113&RS=202002
Benzinga · 4d ago
U.S. debut on horizon for iTeos Therapeutics
Seeking Alpha - Article · 06/25 16:10
Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020
PR Newswire · 06/22 14:00
Phio Pharma Highlights Presentation Of Added Data Supporting Potential Of TIGIT Targeting INTASYL Compound In Tumor Microenvironment At AACR
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today
Benzinga · 06/22 13:07
NIO, SPCE among premarket gainers
Seeking Alpha - Article · 06/22 12:21
PHIO: Roussy's Robert Details Developments in Melanoma Medicine
By John Vandermosten, CFA NASDAQ:PHIO Phio Pharmaceuticals Unveils Clinical Plans for Neoadjuvant Intratumoral INTASYL in Melanoma
Benzinga · 06/15 13:40
PHIO: Roussys Robert Details Developments in Melanoma Medicine
Zacks Small Cap Research · 06/15 10:33
Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th
PR Newswire · 06/08 13:30

Industry

Biotechnology & Medical Research
+2.52%
Pharmaceuticals & Medical Research
+1.64%

Hot Stocks

Symbol
Price
%Change

About PHIO

Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.
More

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.